The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Ipsen (Inst)
Research Funding - Bayer (Inst); BTG (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); Ipsen (Inst); Isotopen Technologien (Inst); Novartis (Inst); Sirtex Medical (Inst); Taiho Pharmaceutical (Inst)
Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - 3DMedcare; Agios; Alignmed; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Boston Scientific; BridgeBio Pharma; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celsion; Cipla; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Genoscience Pharma; Gilead Sciences (I); Halozyme; Halozyme; Hengrui Pharmaceutical; Inovio Pharmaceuticals; Ipsen; Janssen (I); Jazz Pharmaceuticals; Kyowa Hakko Kirin; LAM Therapeutics; Lilly; Loxo (I); Medimmune; Merck Serono; Minapharma; Newlink Genetics (I); Novella Clinical; Onxeo; PCI Biotech; PCI Biotech; Pfizer (I); Pharmacyclics (I); Pharmacyte Biotech (I); Pieris Pharmaceuticals (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; SOBI (I); Targovax (I); Tekmira; Tekmira; twoXAR; Vicus Therapeutics (I); Yakult Pharmaceutical; Yakult Pharmaceutical; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); OncoQuest (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Tarveda Therapeutics
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical
 
Irfan Cicin
No Relationships to Disclose
 
Luigi Bolondi
Honoraria - Bayer; Bracco Diagnostics; Bristol-Myers Squibb; Guerbet; Lilly; Meda Pharmaceuticals; Sirtex Medical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Guerbet; Sirtex Medical
Speakers' Bureau - Bayer; Bracco Diagnostics; Bristol-Myers Squibb; Guerbet; Lilly; Meda Pharmaceuticals; Sirtex Medical
Research Funding - ArQule; Bayer; Bristol-Myers Squibb; Daiichi Sankyo
Travel, Accommodations, Expenses - Bayer; Bracco Diagnostics; Guerbet; Lilly
 
Heinz Josef Klümpen
No Relationships to Disclose
 
Stephen Lam Chan
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis
Speakers' Bureau - Amgen; Bayer; Eisai
Research Funding - Novartis; Sirtex Medical
 
Vincenzo Dadduzio
Consulting or Advisory Role - Ipsen
Travel, Accommodations, Expenses - Amgen; Bayer
 
Steven Milwee
Employment - Exelixis
Stock and Other Ownership Interests - Amgen; Exelixis; FibroGen; GlaxoSmithKline
 
Sarita Dubey
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst)
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Genentech/Roche; Merck; Novartis
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Merck; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca